OncoMatch/Pancreatic Cancer (PDAC)/BRCA1
Pancreatic Cancer (PDAC)BRCA1 Clinical Trials
Germline BRCA1 pathogenic variants occur in approximately 1–3% of pancreatic ductal adenocarcinoma (PDAC) and confer sensitivity to platinum-based chemotherapy and PARP inhibition through homologous recombination deficiency. Olaparib maintenance after platinum-based induction is FDA-approved for germline BRCA1/2-positive metastatic PDAC. Trials explore PARP inhibitor combinations with ATR/CHK1 inhibitors and immunotherapy, and somatic BRCA1 alteration eligibility.
Top recruiting BRCA1 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
University Health Network, Toronto
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins